Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026
Rhea-AI Summary
Senseonics (NASDAQ:SENS) announced participation in the ADA 2026 Scientific Sessions, highlighting its Eversense 365 one-year CGM system.
The company will host an analyst event on June 6, 2026 at 7:00am CT and an oral presentation that afternoon sharing real-world Eversense 365 performance data.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
SENS is up 1.04% while key peers show mixed moves: BFLY (-0.99%), DCTH (-1.19%), RXST (-4.65%), PACB (+1.71%), TCMD (-5.13%). No coordinated sector trend is evident.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 2026 earnings | Positive | -6.2% | Strong revenue growth and raised guidance followed by a -6.16% price reaction. |
| May 04 | Equity offering close | Negative | -0.2% | Closing of $92M public offering with slight -0.2% dilution-driven weakness. |
| May 04 | Debt facility amendment | Positive | -1.8% | Loan capacity raised to $140M but shares fell -1.76% post-announcement. |
| May 01 | Earnings call scheduling | Neutral | -22.8% | Routine Q1 call scheduling coincided with a -22.84% move. |
| Apr 30 | Equity offering pricing | Negative | -22.8% | Pricing of $80M stock and warrant offering matched a -22.84% selloff. |
Recent news, including strong growth and multiple financings, has often been followed by negative 1-day price reactions, even on generally constructive updates.
Over the last months, SENS reported Q1 2026 revenue of $11.7M (up 87% YoY) and raised 2026 revenue guidance to $60M–$64M, yet the stock fell 6.16% the next day. Multiple equity offerings totaling at least $80M and $92M saw sharp declines of 22.84% and a modest 0.2% drop, while an expanded loan facility to $140M and an earnings call scheduling also coincided with negative reactions. Today’s ADA-focused announcement fits into an ongoing commercialization and financing narrative around Eversense 365.
Regulatory & Risk Context
An effective Form S-3 shelf filed on Aug 6, 2025 allows SENS to issue up to $300 million of securities, including a $100 million ATM program, with at least two 424B5 takedowns in 2026. This structure provides capital-raising flexibility that has recently been used alongside public offerings.
Market Pulse Summary
This announcement centers on visibility for the Eversense 365 one‑year implantable CGM at ADA 2026, via an analyst event and an oral presentation on real‑world performance in open and closed loop systems. It follows recent financings and an expanded loan facility supporting commercialization. Investors may watch for detailed clinical metrics from the ADA data, updates on European and U.S. uptake, and any commentary that builds on prior 2026 revenue guidance of $60M–$64M.
Key Terms
continuous glucose monitoring (cgm) medical
real world evidence medical
closed loop systems medical
AI-generated analysis. Not financial advice.
GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today highlights two key company events during the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5-8 in New Orleans, Louisiana. Senseonics will be hosting an analyst event to discuss the Eversense 365 platform, as well as an oral presentation on the ADA program discussing real world evidence of the world’s first and only one year CGM system.
Analyst Event Details
Senseonics will host an in-person and virtual analyst event in conjunction with ADA 2026, reviewing recent milestones and provide a comprehensive update on Eversense 365 commercial progress. This will include the European launch, integration with the Sequel twiist pump, pipeline development activities (including the Gemini and Freedom programs), and clinical data being presented at ADA. It will feature physician and key opinion leader Dr. David T. Ahn, who will discuss his experience with Eversense 365, including the insertion procedure and patient satisfaction. Senseonics management will provide financial and high-level operation updates.
The event will take place at the New Orleans Marriott Warehouse District, with a live webcast option, at 7:00am CT on Saturday, June 6, 2026. To register, click here.
Oral Presentation Details
On the same day, Francine Kaufman, M.D., Chief Medical Officer at Senseonics, will be hosting an oral presentation on the ADA Scientific Sessions program titled “Real-World Evaluation of the Implantable One-Year Eversense 365 CGM System” which explores new data evaluating Eversense 365 performance and impact in open and closed loop systems in the U.S.
Title: Real-World Evaluation of the Implantable One-Year Eversense 365 CGM System
Session: Oral presentation (1173-OR)
Presenter: Francine Kaufman, M.D., Chief Medical Office at Senseonics
Date / Time: Saturday June 6, 2:30-2:45pm CT
Location: La Nouvelle Orleans C (Level 2)
Additional information about the ADA 2026 Scientific Sessions is available at the ADA meeting website (American Diabetes Association).
About Eversense
Eversense 365 is developed by Senseonics and, as the only implantable CGM available, offers patients a truly differentiated CGM experience, providing One Year of exceptionally accurate monitoring with minimal interruptions. It benefits endocrinologists and care teams by offering their patients confidence in decision making, long-term peace of mind and enhanced quality of life with just one CGM. The unique approach also allows people to overcome common frustrations and interruptions experienced with traditional, short-term CGMs, so that patients can focus on managing their diabetes and not their CGM.
The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see https://www.eversensediabetes.com/safety-info/.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development, manufacturing and commercialization of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM system Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Media Contact
Tim Stamper
FTI Consulting
Tim.Stamper@senseonics.com / Eversense365@FTIConsulting.com
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
